Keythera Pharmaceuticals, as a clinical-stage innovative pharmaceutical company rooted in China with a global vision, has achieved breakthrough progress in areas of unmet clinical needs such as oncology and autoimmune diseases. This is accomplished through its proprietary Affinity-based Mass Spectrometry Screening platform. The company has established multiple differentiated pipelines with global competitiveness, three of which have advanced to clinical development stages, demonstrating its highly efficient R&D capabilities.